Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer

Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching*, Wolfgang Janni, Isabell Witzel, Christoph Thomssen, Milena Beierlein, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Achim WöckelHans Christian Kolberg, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Andreas Schneeweiss, Johannes Ettl, Rachel Würstlein, David Krug, Florin Andrei Taran, Diana Lüftner

*Corresponding author for this work


With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Issue number6
Pages (from-to)653-663
Number of pages11
Publication statusPublished - 12.04.2023

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

  • 205-21 Gynaecology and Obstetrics

Cite this